Screener
Vera Therapeutics VERA Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Vera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Vera Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:33 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212143
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (1,823) | (1,792) |
| Other (expense) income, net | (432) | 386 |
| Total other income, net | 4,100 | 5,500 |
| Net loss | $(121,032) | $(51,694) |
| Other comprehensive income: | ||
| Change in unrealized gains and losses on marketable securities | (942) | 261 |
| Comprehensive loss | $(121,974) | $(51,433) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.69) | $(0.81) |
Item 1. Financial Statements
FAQ
- What is Vera Therapeutics's net income?
- Vera Therapeutics (VERA) reported net income of -$121.03M in Q1 2026.
- How has Vera Therapeutics's net income changed year-over-year?
- Vera Therapeutics's net income decreased by 134.1% year-over-year, from -$51.69M to -$121.03M.
- What is the long-term trend for Vera Therapeutics's net income?
- Over 4 years (2021 to 2025), Vera Therapeutics's net income has grown at a 74.1% compound annual growth rate (CAGR), from -$32.61M to -$299.62M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Vera Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude